secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALIMERA SCIENCES INC (—)
CIK:        0001267602
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001104659-24-100189
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alimera Sciences completes merger with ANI Pharmaceuticals for $5.50 per share plus CVRs
--------------------------------------------------------------------------------

- Merger completed on September 16, 2024; shareholders receive $5.50 per share cash and one CVR.
- CVRs tied to net revenue milestones for ILUVIEN and YUTIQ: $140M in 2026 or $160M in 2027, with contingent payments.
- Nasdaq delisting requested; company to file Form 25 and Form 15 to suspend SEC reporting obligations.
- All directors resigned; new directors from merger subsidiary appointed; existing officers retained.
- Loan agreements with SLR Investment Corp. repaid and terminated in connection with the merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/tm2424081d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-100189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer